Metabolic emergencies

被引:37
作者
Spinazzé, S [1 ]
Schrijvers, D
机构
[1] START Project, Aosta, Italy
[2] Osped Reginale, Aosta, Italy
[3] ZNA Middelheim, Antwerp, Belgium
关键词
hypercalcaemia; tumour lysis syndrome; metabolic emergencies;
D O I
10.1016/j.critrevonc.2005.04.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Life-threatening metabolic complications observed in cancer patients are: hypercalcaemia, hyponatremia, hyperurcaemia, tumour lysis syndrome, hypoglycaemia, hyperuremia and hypercreatininemia secondary to renal failure, hyperammoniemia, lactic acidosis and adrenal failure. They may be associated with any kind of neoplastic disease causing dysfunction of vital organs, which can be determined by neoplastic spread, anti-cancer treatment or, more rarely, by paraneoplastic phenomena. The clinical presentation of metabolic complications is typically aspecific. Encephalopathy, raging from mild confusion to coma, is the most common and clinically most severe symptom. The severity of consciousness impairment is related to both the rate of onset and the magnitude of the metabolic disorder. The definitive diagnosis will be established by laboratory examination and radiological work-LIP. Cancer patients presenting metabolic should be referred to oncologic departments or intensive care units. The treatment of metabolic disorders include: prophylactic measures, emergency measures to preserve vital functions and to restore biological parameters and the treatment of the underlying primary. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:79 / 89
页数:11
相关论文
共 47 条
[1]   Acute tumor lysis syndrome [J].
Altman, A .
SEMINARS IN ONCOLOGY, 2001, 28 (02) :3-8
[2]   Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, M ;
Blacklock, H ;
Bell, R ;
Simeone, JF ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602
[3]   A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis [J].
Berghmans, T ;
Paesmans, M ;
Body, JJ .
SUPPORTIVE CARE IN CANCER, 2000, 8 (03) :192-197
[4]  
Body Jean-Jacques, 2000, Cancer, V88, P3054, DOI 10.1002/1097-0142(20000615)88:12+<3054::AID-CNCR23>3.0.CO
[5]  
2-Z
[6]   Current use of bisphosphonates in oncology [J].
Body, JJ ;
Bartl, R ;
Burckhardt, P ;
Delmas, PD ;
Diel, IJ ;
Fleisch, H ;
Kanis, JA ;
Kyle, RA ;
Mundy, GR ;
Paterson, AHG ;
Rubens, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) :3890-3899
[7]   Symptoms of hypoglycemia, thresholds for their occurrence, and hypoglycemia unawareness [J].
Cryer, PE .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1999, 28 (03) :495-+
[8]   TREATMENT OF THE SYNDROME OF INAPPROPRIATE SECRETION OF ANTI-DIURETIC HORMONE WITH FUROSEMIDE [J].
DECAUX, G ;
WATERLOT, Y ;
GENETTE, F ;
MOCKEL, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (06) :329-330
[9]   Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985 [J].
Decaux, G .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2001, 138 (01) :18-21
[10]   Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide [J].
Decaux, G .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (07) :582-584